Gilead Sciences (GILD) Tops Q4 EPS by 1c; Authorizes $5B Buyback Plan; Receives 'Refuse to File' Notification from FDA

January 25, 2011 4:08 PM EST
Gilead Sciences Inc. (NASDAQ: GILD) reported Q4 EPS of $0.95, $0.01 better than the analyst estimate of $0.94. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.99 billion.

The company also announced that its Board has authorized an additional 3-year $5 billion buyback program.

In a separate press release, Gilead also announced that it received a "refuse to file" notification from the FDA on its NDA for single-tablet regimen of Truvada and TMC278.

UPDATE: Gilead shares are down about 2% in the after-hours session. The stock last traded at $37.44.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, FDA, Hot Earnings, Stock Buybacks

Add Your Comment